Braveheart Bio, Inc. Common Stock

Hengrui Pharma announced its financial results for the first half of 2026, reporting revenue of RMB15.46 billion and net profit attributable to shareholders of RMB4.47 billion, up 0.34%. Innovative drug sales increased by 16.38% year-over-year and accounted for 63.16% of total drug sales, with non-oncology innovative drug sales surging 73.97%. The company obtained seven innovation-related approvals in China, including two Class 1 innovative medicines, and reported positive Phase III results for its GLP-1/GIP dual receptor agonist ribupatide injection and oral GLP-1 receptor agonist HRS-7535. Since 2023, Hengrui has completed 13 overseas business development transactions with a total potential value of approximately US$42 billion, and its NewCo partners Kailera Therapeutics and Braveheart Bio both listed on Nasdaq in 2026.

Braveheart Bio completed its initial public offering, raising about $382.5 million and listing on the Nasdaq Global Market. The company was added to the NASDAQ Composite Index shortly after the IPO, and it subsequently filed a $439.4 million shelf registration to provide flexibility for future capital raises. Braveheart Bio is a clinical-stage biopharmaceutical company focused on therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases, with less than $1 million in revenue and under three years of financial data.